Skip to main content
SpringerLink
Log in

DNA Topoisomerase II Inhibitors

  • Chapter
Cancer Therapeutics

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

DNA topoisomerases represent a major focus of research not only for cancer chemotherapy, but also for gene regulation, cell cycle, mitosis, and chromosome structure. A number of reviews have been written on the subject (1–8).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Wang JC. DNA topoisomerases. Annu Rev Biochem 1985; 54: 665–697.

    Article  PubMed  CAS  Google Scholar 

  2. Wang JC. Recent studies of DNA topoisomerases. Biochim Biophys Acta 1987; 909: 1–9.

    Article  PubMed  CAS  Google Scholar 

  3. Wang JC. DNA topoisomerases: why so many? J Bio! Chem 1991; 266: 6659–6662.

    CAS  Google Scholar 

  4. Gupta M, Fujimori A, Pommier Y. Eukaryotic DNA topoisomerases I. Biochim Biophys Acta 1995; 1262: 1–14.

    Article  PubMed  Google Scholar 

  5. Pommier Y, Leteurtre F, Fesen M, Fujimori A, Bertrand R, Solary E, Kohlhagen G, Kohn KW. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 1994; 12: 530–542.

    Article  PubMed  CAS  Google Scholar 

  6. Pommier Y. DNA topoisomerases I and II in cancer chemotherapy: update and perspectives. Cancer Chemother Pharmaco 1993; 32: 103–108.

    Article  CAS  Google Scholar 

  7. Watt PM, Hickson ID. Structure and function of type II DNA topoisomerases. Biochem J 1994; 303: 681–695.

    PubMed  CAS  Google Scholar 

  8. Osheroff N, Zechierich EL, Gale KC. Catalytic function of DNA topoisomerase II. BioEssays 1991; 13: 269–275.

    Article  PubMed  CAS  Google Scholar 

  9. Caron PR, Wang JC. DNA topoisomerases as target of therapeutics: a structural overview. In: Andoh T, Ikeda H, Oguro M, eds. Molecular Biology of DNA Topoisomerases and Its Application to Chemotherapy. Boca Raton, FL: CRC. 1993: 1–18.

    Google Scholar 

  10. Champoux J. Mechanistic aspects of type-I topoisomerases. In: Wang JC, Cozarelli NR, eds. DNA topology and its biological effects. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press. 1990: 217–242.

    Google Scholar 

  11. Kohn KW, Pommier Y, Kerrigan D, Markovits J, Covey JM. Topoisomerase II as a target of anticancer drug action in mammalian cells. NCI Monographs 1987; 4: 61–71.

    PubMed  Google Scholar 

  12. Pommier Y, Kohn KW. Topoisomerase II inhibition by antitumor intercalators and demethylepipodophyllotoxins. In: Glazer RI, eds. Developments in Cancer Chemotherapy. Boca Raton, FL: CRC. 1989: 175–196.

    Google Scholar 

  13. Pommier Y, Tanizawa A. Mammalian DNA topoisomerase I and its inhibitors. In: Hickman J, Tritton T, eds. Cancer Chemotherapy. Oxford: Blackwell Scientific Publications. 1993: 214–250.

    Google Scholar 

  14. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985; 260:14, 873–14, 878.

    Google Scholar 

  15. Trask DK, Muller MT. Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D. Proc Natl Acad Sci USA 1988; 85: 1417–1421.

    Article  PubMed  CAS  Google Scholar 

  16. Wasserman K, Markovits J, Jaxel C, Capranico G, Kohn KW, Pommier Y. Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II. Mol Pharmacol 1990; 38: 38–45.

    Google Scholar 

  17. Poddevin B, Riou J-F, Lavelle F, Pommier Y. Dual topoisomerase I and II inhibition by intoplicine (RP-60475) a new antitumor agent in early clinical trials. Mol Pharmacol 1993; 44: 767–774.

    Google Scholar 

  18. Yamashita Y, Kawada S-Z, Fujii N, Nakano H. Induction of mammalian topoisomerase I and II mediated DNA cleavage by saintopin, a new antitumor agent from fungus. Biochemistry 1991; 30: 5838–5845.

    Article  PubMed  CAS  Google Scholar 

  19. Leteurtre F, Fujimori A, Tanizawa A, Chhabra A, Mazumder A, Kohlhagen G, Nakano H, Pommier Y. Saintopin, a dual inhibitor of DNA topoisomerases I and II, as a probe for drug-enzyme interactions. J Bio! Chem 1994; 269:28,702–28,707.

    Google Scholar 

  20. Roca J, Wang JC. DNA transport by a type II DNA topoisomerase: evidence in favor of a two-gate mechanism. Cell 1994; 77: 609–616.

    Article  PubMed  CAS  Google Scholar 

  21. Adachi Y, Luke M, Laemmli UK. Chromosome assembly in vitro: topoisomerase II is required for condensation. Cell 1991; 64: 137–148.

    Article  PubMed  CAS  Google Scholar 

  22. Earnshaw WC, Heck MM. Localization of topoisomerase II in mitotic chromosomes. J Cell Bio 1985; 100: 1716–1725.

    Article  CAS  Google Scholar 

  23. Gasser SM, Laroche T, Falquet J, Boy de la Tour E, Laemmli UK. Metaphase chromosome structure. Involvement of topoisomerase II. J Mol Biol 1986; 188: 613–629.

    Article  PubMed  CAS  Google Scholar 

  24. Hirano T, Mitchison TJ. Topoisomerase II does not play a scaffolding role in the organization of mitotic chromosomes assembled in Xenopus egg extracts. J Cell Bio 1993; 120: 601–612.

    Article  CAS  Google Scholar 

  25. DiNardo S, Voelkel K, Sternglanz R. DNA topoisomerase II mutant of Saccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication. Proc Nat! Acad Sci USA 1984; 81: 2616–2620.

    Article  PubMed  CAS  Google Scholar 

  26. Holm C, Stearns T, Botstein D. DNA topoisomerase II must act at mitosis to prevent nondisjunction and chromosome breakage. Mol Cell Bio 1989; 9: 159–168.

    CAS  Google Scholar 

  27. Uemura T, Ohkura H, Adachi Y, Morino K, Shiozaki K, Yanagida M. DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe. Cell 1987; 50: 917–925.

    Article  CAS  Google Scholar 

  28. Rose D, Holm C. Meiosis-specific arrest revealed in DNA topoisomerase II mutants. Mol Cell Bio 1993; 13: 3445–3455.

    CAS  Google Scholar 

  29. Moens PB, Earnshaw WC. Anti-topoisomerase II recognizes meiotic chromosome cores. Chromosoma 1990; 98: 317–322.

    Article  Google Scholar 

  30. Shamu CE, Murray AM. Sister chromatid separation in frog egg extracts requires DNA topoisomerase II activity during anaphase. J Cell Bio 1992; 117: 921–934.

    Article  CAS  Google Scholar 

  31. Wood ER, Earnshaw WC. Mitotic chromatin condensation in vitro using somatic cell extracts and nuclei with variable levels of endogenous topoisomerase II. J Cell Bio 1990; 111: 2839–2850.

    Article  CAS  Google Scholar 

  32. Newport J. Nuclear reconstitution in vitro: stages of assembly around protein-free DNA. Cell 1987; 48: 205–217.

    Article  PubMed  CAS  Google Scholar 

  33. Newport J, Spann T. Disassembly of the nucleus in the mitotic extracts: membrane vesiculization, lamin disassembly, and chromosome condensation are independent processes. Cell 1987; 48: 219–230.

    Article  PubMed  CAS  Google Scholar 

  34. Downes CS, Mullinger AM, Johnson RT. Inhibitors of DNA topoisomerase II prevent chromatid separation in mammalian cells but do not prevent exit from mitosis. Proc Natl Acad Sci USA 1991; 88: 8895–8899.

    Article  PubMed  CAS  Google Scholar 

  35. Swedlow JR, Sedat JW, Agard DA. Multiple chromosomal populations of topoisomerase II detected in vivo by time-lapse, three-dimensional wide-field microscopy. Cell 1993; 73: 97–108.

    Article  PubMed  CAS  Google Scholar 

  36. Heck MMS, Hittelman WN, Earnshaw WC. In vivo phosphorylation of the 170-kDa form of eukaryotic DNA topoisomerase II. JBiol Chem 1989; 264:15,161–15,164.

    Google Scholar 

  37. Taagepera S, Rao PN, Drake FH, Gorbsky GJ. DNA topoisomerase II-alpha is the major chromosome protein recognized by the mitotic phosphoprotein antibody MPM-2. Proc Nat! Acad Sci USA 1993; 90: 8407–8411.

    Article  PubMed  CAS  Google Scholar 

  38. Kuang J, Ashorn CL. At least two kinases phosphorylate the MPM-2 epitope during Xenopus oocyte maturation. J Cell Bio 1993; 123: 859–868.

    Article  CAS  Google Scholar 

  39. Cardenas ME, Dang Q, Glover CVC, Gasser SM. Casein kinase II phosphorylates the eukaryote-specific C-terminal domain of topoisomerase II in vivo. EMBO J 1992; 11: 1785–1796.

    PubMed  CAS  Google Scholar 

  40. Bojanowski K, Filhol O, Cochet C, Chambaz EM, Larsen AK. DNA topoisomerase II and casein kinase II associate in a molecular complex that is catalytically active. J Biol Chem 1994; 268:22, 920–22, 926.

    Google Scholar 

  41. Ackerman P, Glover CV, Osheroff N. Phosphorylation of DNA topoisomerase II in vivo and in total homogenates of Drosophila Kc cells. The role of casein kinsae II. J Bio! Chem 1988; 263:12,653–12,660.

    Google Scholar 

  42. Corbett AH, Fernald AW, Osheroff N. Protein kinase C modulates the catalytic activity of topoisomerase II by enhancing the rate of ATP hydrolysis: evidence for a common mechanism by regulation by phosphorylation. J Biol Chem 1993; 32: 2090–2097.

    CAS  Google Scholar 

  43. De Vore RF, Corbett AH, Osheroff N. Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4 ’-(9-acridinylamino)methane-sulfon-m-anisidide. Cancer Res 1992; 52: 2156–2161.

    Google Scholar 

  44. Takano H, Kohno K, Ono M, Uchida Y, Kuwano M. Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human KB carcinoma cells. Cancer Res 1991; 51: 3951–3957.

    PubMed  CAS  Google Scholar 

  45. Drake FH, Hofmann GA, Bartus HF, Mattem MR, Crooke ST, Mirabelli CK. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 1989; 28: 8154–8160.

    Article  PubMed  CAS  Google Scholar 

  46. Tsutsui K, Tsutsui K, Okada S, Watanabe M, Shohmori T, Seki S, Inoue Y. Molecular cloning of partial cDNAs for rat DNA topoisomerase II isoforms and their differential expression in brain development. J Bio! Chem 1993; 268:19,076–19,083.

    Google Scholar 

  47. Woessner RD, Mattem MR, Mirabelli CK, Johnson RK, Drake FH. Proliferation-and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ 1991; 2: 209–214.

    PubMed  CAS  Google Scholar 

  48. Capranico G, Tinelli S, Austin CA, Fisher ML, Zunino F. Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. Biochim Biophys Acta 1992; 1132: 43–48.

    Article  PubMed  CAS  Google Scholar 

  49. Negri C, Scovassi AI, Braghetti A, Guano F, Astaldi Ricotti GC. DNA topoisomerase II beta: stability and distribution in different animal cells in comparison to DNA topoisomerase I and II alpha. Exp Cell Res 1993; 206: 128–133.

    Article  PubMed  CAS  Google Scholar 

  50. Petrov P, Drake F, Loranger A, Huang W, Hancock R. Localization of DNA topoisomerase II in chinese hamster fibroblasts by confocal and electron microscopy. Exp Cell Res 1993; 204: 73–81.

    Article  PubMed  CAS  Google Scholar 

  51. Tsai-Pflugfelder M, Liu LF, Liu AA, Tewey KM, Whang-Peng J, Knutsen T, Huebner K, Croce CM, Wang JC. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21–22. Proc Natl. Acad Sci USA 1988; 85: 7177–7181.

    Article  PubMed  CAS  Google Scholar 

  52. Jenkins JR, Ayton P, Jones T, Davies SL, Simmons DL, Harris AL, Sheer D, Hickson ID. Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Res 1992; 20: 5587–5592.

    Article  PubMed  CAS  Google Scholar 

  53. Patel S, Fisher LM. Novel HeLa topoisomerase II is the II beta isoform: complete coding sequence and homology with other type II topoisomerases. Br J Cancer 1993; 67: 456–463.

    Article  PubMed  CAS  Google Scholar 

  54. Tan KB, Dorman TE, Falls KM, Chung TDY, Mirabelli CK, Crooke ST, Mao J-I. Topoisomerase II-alpha and topoisomerase II-beta genes: characterization and mapping to human chromosomes 17 and 3, respectively. Cancer Res 1992; 52: 231–234.

    PubMed  CAS  Google Scholar 

  55. Austin CA, Marsh KL, Wasserman RA, Willmore E, Sayer PJ, Wang JC, Fisher LM. Expression, domain structure, and enzymatic properties of an active recombinant human DNA topoisomerase II beta. J Biol Chem 1995; 270:15,739–15,746.

    Google Scholar 

  56. Zechiedrich EL, Osheroff N. Eukaryotic topoisomerases recognize nucleic acid topology by preferentially interacting with DNA crossovers. EMBO J 1990; 9: 4555–4562.

    PubMed  CAS  Google Scholar 

  57. Hsieh C-H, Griffith JD. The terminus of SV40 DNA replication and transcription contains a sharp sequence-directed curve. Cell 1988; 52: 535–544.

    Article  PubMed  CAS  Google Scholar 

  58. Howard MT, Lee MP, Hsieh T-S, Griffith JD. Drosophila topoisomerase II-DNA interactions are affected by DNA structure. J Mol Biol 1991; 217: 53–62.

    Article  PubMed  CAS  Google Scholar 

  59. Sander M, Hsieh TS. Drosophilia topoisomerase II double-strand DNA cleavage: analysis of DNA sequence homology at the cleavage site. Nucleic Acids Res 1985; 13: 1057–1072.

    Article  PubMed  CAS  Google Scholar 

  60. Spitzner JR, Muller MT. A consensus sequence for cleavage by vertebrate DNA topoisomerase I. Nucleic Acids Res 1988; 16: 5533–5556.

    Article  PubMed  CAS  Google Scholar 

  61. Pommier Y, Capranico G, Orr A, Kohn KW. Distribution of topoisomerase II cleavage sites in SV40 DNA and the effects of drugs. J Moi Biol 1991; 222: 909–924.

    Article  CAS  Google Scholar 

  62. Pommier Y, Capranico G, Orr A, Kohn KW. Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine and teniposide. Nucleic Acids Res 1991; 19: 5973–5980.

    Article  PubMed  CAS  Google Scholar 

  63. Pommier Y, Kerrigan D, Kohn D. Topological complexes between DNA and topoisomerase II and effects of polyamines. Biochemistry 1989; 28: 995–1002.

    Article  PubMed  CAS  Google Scholar 

  64. Corbett AH, Zechiedrich EL, Osheroff N. A role for the passage helix in the DNA cleavage reaction of eukaryotic topoisomerase II. J Bio! Chem 1992; 267: 683–686.

    CAS  Google Scholar 

  65. Roca J, Ishida R, Berger JM, Andoh T, Wang JC. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA 1994; 91: 1781–1785.

    Article  PubMed  CAS  Google Scholar 

  66. Corbett AH, Osheroff N. When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem Res Toxico 1993; 6: 585–597.

    Article  CAS  Google Scholar 

  67. Froelich-Ammon SJ, Osheroff N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J Biol Chem 1995; 270:21, 429–21, 432.

    Google Scholar 

  68. Kohn KW. Principles and practice of DNA filter elution. Pharmacol Ther 1991; 49: 55–77.

    Article  PubMed  Google Scholar 

  69. Bertrand R, Pommier Y. Assessment of DNA damage in mammalian cells by DNA filtration methods. In: Studzinski G, Ed. Cell Growth and Apoptosis: A Practical Approach. Oxford: IRL, Oxford University Press. 1995: 96–117.

    Google Scholar 

  70. Trask DK, DiDonato JA, Muller MT. Rapid detection and isolation of covalent DNA/protein complexes: application to topoisomerase I and II. EMBO J 1984; 3: 671–676.

    PubMed  CAS  Google Scholar 

  71. Rowe TC, Chen GL, Hsiang YH, Liu LF. DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. Cancer Res 1986; 46: 2021–2026.

    PubMed  CAS  Google Scholar 

  72. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989; 58: 351–375.

    Article  PubMed  CAS  Google Scholar 

  73. Robinson MJ, Martin BA, Gootz TD, McGuirk PR, Moynihan M, Sutcliffe JA, Osheroff N. Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme mediated DNA cleavage. J Bio! Chem 1991; 266:14,585–14,592.

    Google Scholar 

  74. Robinson MJ, Corbett AH, Osheroff N. Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase H. Biochemistry 1993; 32: 3638–3643.

    Article  PubMed  CAS  Google Scholar 

  75. Robinson MJ, Osheroff N. Effects of antineoplastic drugs on the post-strand passage DNA cleavage/religation equilibrium of topoisomerase II. Biochemistry 1991; 30: 1807–1813.

    Article  PubMed  CAS  Google Scholar 

  76. Zwelling LA, Hinds M, Chan D, Mayes J, Sie KL, Parder E, Silberman L, Radcliffe A, Beran M, Blick M. Characterization of an amsacrine-resistant line of human leukemia cells. J Bio! Chem 1989; 264:16,411–16,420.

    Google Scholar 

  77. Mayes J, Hinds M, Soares L, Altschuler E, Kim P, Zwelling LA. Further characterization of an amsacrine-resistant line of HL-60 human leukemia cells and its topoisomerase II. Biochem. Pharmacol 1993; 46: 599–607.

    Article  Google Scholar 

  78. Huff AC, Ward RE, Kreuzer KN. Mutational alterations of the breakage/resealing subunits of bacteriophage T4 DNA topoisomerase confers resistance to antitumor agent m-AMSA. Mol Gen Genet 1990; 221: 27–32.

    Article  PubMed  CAS  Google Scholar 

  79. Huff AC, Kreuzer KN. Evidence for a common mechanism of action of antitumor and antibacterial agents that inhibit type II DNA topoisomerases. J Bio! Chem 1990; 265:20,496–20,505.

    Google Scholar 

  80. Crenshaw DG, Hsieh T-S. Function of the hydrophilic carboxyl terminus of type II DNA topoisomerase from Drosophila melanogaster. J Biol Chem 1993; 28:21,328–21,334.

    Google Scholar 

  81. Harker WG, Slade DL, Parr RL, Holguin MH. Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase IIa messenger RNA and protein in human HL-60 leukemai cells selected for resistance to mitoxantrone. Cancer Res 1995; 55: 4962–4971.

    PubMed  CAS  Google Scholar 

  82. Mirski SEL, Cole SPC. Cytoplasmic localization of a mutant Mr 160,000 topoisomerase II alpha is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line. Cancer Res 1995; 55: 2129–2134.

    PubMed  CAS  Google Scholar 

  83. Pommier Y, Capranico G, Kohn KW. Local DNA sequence requirements for topoisomerase II-induced DNA cleavage produced by amsacrine and teniposide. Proc Am Assoc Cancer Res 1991; 32: 335.

    Google Scholar 

  84. Pommier Y, Kohn KW, Capranico G, Jaxel C. Base sequence selectivity of topoisomerase inhibitors suggests a common model for drug action. In: Andoh T, Ikeda H, Oguro M, eds. Molecular Biology of DNA Topoisomerase and Its Application to Chemotherapy. Boca Raton, FL: CRC. 1993: 215–227.

    Google Scholar 

  85. Capranico G, Kohn KW, Pommier Y. Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acids Res 1990; 18: 6611–6619.

    Article  PubMed  CAS  Google Scholar 

  86. Capranico G, Tinelli S, Zunino F, Kohn KW, Pommier Y. Effects of base mutations on topoisomerase II DNA cleavage stimulated by mAMSA in short DNA oligomers. Biochemistry 1993; 32: 145–152.

    Article  PubMed  CAS  Google Scholar 

  87. Capranico G, De Isabella T, Tinelli S, Bigioni S, Zunino F. Similar sequence specificity of mitoxantrone and VM-26 stimulation of in vitro DNA cleavage by mammalian DNA topoisomerase II. Biochemistry 1993; 32: 3032–3048.

    Google Scholar 

  88. Capranico G, Palumbo M, Tinelli S, Zunino F. Unique sequence specificity by topoisomerase II DNA cleavage stimulation and DNA binding mode of streptonigrin. J Biol Chem 1994; 40:25, 004–25, 009.

    Google Scholar 

  89. Leteurtre F, Kohlhagen G, Pommier Y. Streptonigrin-induced topoisomerase II sites exhibit base preference in the middle of the enzyme stagger. Biochem Biophys Res Commun 1994; 203: 1259–1267.

    Article  PubMed  CAS  Google Scholar 

  90. Fosse P, Rene B, Le Bret M, Paoletti C, Saucier J-M. Sequence requirements for mammalian topoisomerase II mediated DNA cleavage stimulated by an ellipticine derivative. Nucleic Acids Res 1991; 19: 2861–2868.

    Article  PubMed  CAS  Google Scholar 

  91. Freudenreich CH, Kreuzer KN. Mutational analysis of a type II topoisomerase cleavage site: distinct requirements for enzyme and inhibitors. EMBO J 1993; 12: 2085–2097.

    PubMed  CAS  Google Scholar 

  92. Freudenreich CH, Kreuzer KN. Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex. Proc Natl Acad Sci USA 1994; 91:11, 007–11, 011.

    Google Scholar 

  93. Jaxel C, Capranico G, Kerrigan D, Kohn KW, Pommier Y. Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J Biol Chem 1991; 266: 20, 418–20, 423.

    Google Scholar 

  94. Tanizawa A, Kohn KW, Pommier Y. Induction of cleavage in topoisomerase I cDNA by topoisomerase I enzymes from calf thymus and wheat germ in the presence and absence of camptothecin. Nucleic Acids Res 1993; 21: 5157–5166.

    Article  PubMed  CAS  Google Scholar 

  95. Pommier Y, Kohlhagen G, Kohn F, Leteurtre F, Wani MC, Wall ME. Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites. Proc Nat! Acad Sci USA 1995; 92: 8861–8865.

    Article  PubMed  CAS  Google Scholar 

  96. Beck WT, Danks MK. Mechanisms of resistance to drugs that inhibit DNA topoisomerases. Semin Cancer Bio 1991; 2: 235–244.

    CAS  Google Scholar 

  97. Granzen B, Graves DE, Baguley BC, Danks MK, Beck WT. Structure-activity studies of amsacrine analogs in drug resistant human leukemia cell lines expressing either altered DNA topoisomerase II or P-glycoprotein. Onco! Res 1993; 4: 489–496.

    Google Scholar 

  98. Marquardt D, McCrone S, Center MS. Mechanisms of multidrug resistance in HL60 cells: detection of resistance-associated proteins with antibodies against synthetic peptides that correspond to the deduced sequence of P-glycoprotein. Cancer Res 1990; 50: 1426–1430.

    PubMed  Google Scholar 

  99. Barrand MA, Heppell-Parton AC, Wright KA, Rabbitts PH, Twentyman PR. A 190-kilodalton protein overexpressed in non-P-glycoprotein-containing multidrug-resistant cells and its relationship to the MRP gene. J Nat! Cancer Inst 1994; 86: 110–117.

    Article  PubMed  CAS  Google Scholar 

  100. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line (see comments). Science (Washington, DC) 1992; 258: 1650–1654.

    Article  CAS  Google Scholar 

  101. Schneider E, Horton JK, Yang CH, Nakagawa M, Cowan KH. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res 1994; 54: 152–158.

    PubMed  CAS  Google Scholar 

  102. Binaschi M, Supino R, Gambetta RA, Giaccone G, Prosperi E, Capranico G, Cataldo I, Zunino F. MRP gene overexpression in a human doxorubicin-resistant SCLC cell line: alterations in cellular pharmacokinetics and in pattern of cross-resistance. hit J Cancer 1995; 62: 84–89.

    CAS  Google Scholar 

  103. Cragg G, Suffness M. Metabolism of plant-derived anticancer agents. Pharmaco! Ther 1988; 37: 425–461.

    Article  CAS  Google Scholar 

  104. Bendixen C, Thomsen B, Alsner J, Westergaard O. Camptothecin-stabilized topoisomerase I-DNA adducts cause premature termination of transcription. Biochemistry 1990; 29: 5613–5619.

    Article  PubMed  CAS  Google Scholar 

  105. Been MD, Burgess RR, Champoux JJ. Nucleotide sequence preference at rat liver and wheat germ type 1 DNA topoisomerase breakage sites in duplex SV40 DNA. Nucleic Acids Res 1984; 12: 3097–3114.

    Article  PubMed  CAS  Google Scholar 

  106. Loike JD, Brewer CF, Sternlicht H, Gensler WJ, Horwitz SB. Structure-activity study of the inhibition of microtubule assembly in vitro by podophyllotoxin and its congeners. Cancer Res 1978; 38: 2688–2693.

    PubMed  CAS  Google Scholar 

  107. Long BH, Musial ST, Brattain MG. Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16–213 and VM26: a quantitative structure-activity relationship. Biochemistry 1984; 23: 1183–1188.

    Article  PubMed  CAS  Google Scholar 

  108. Sinha BK, Polita PM, Eliot HM, Kerrigan D, Pommier Y. Structure-activity relations, cytotoxicity and topoisomerase II dependent DNA cleavage induced by pendulum ring analogues of etoposide. Eur J Cancer 1990; 26: 590–593.

    Article  PubMed  CAS  Google Scholar 

  109. Chen GL, Yang L, Rowe TC, Halligan BD, Tewey KM, Liu LF. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 1984; 259:13, 560–13, 566.

    Google Scholar 

  110. Leteurtre F, Madalengoitia J, Orr A, Guzi TJ, Lehnert E, Macdonald T, Pommier Y. Rational design and molecular effects of a new topoisomerase II inhibitor, azatoxin. Cancer Res 1992; 52: 4478–4483.

    PubMed  CAS  Google Scholar 

  111. Pommier Y, Orr A, Kohn KW, Riou JF. Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc proto-oncogene. Cancer Res 1992; 52: 3125–3130.

    PubMed  CAS  Google Scholar 

  112. Kerrigan D, Pommier Y, Kohn KW. Protein-linked DNA strand breaks produced by etoposide and teniposide in mouse L1210 and human VA-13 and HT-29 cell lines: relationship to cytotoxicity. NCI Monographs 1987; 4: 117–121.

    PubMed  Google Scholar 

  113. Long BH, Musial ST, Brattain MG. Single-and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide. Cancer Res 1985; 45: 3106–3112.

    PubMed  CAS  Google Scholar 

  114. Capranico G, Zunino F, Kohn KW, Pommier Y. Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA affinity and cytotoxicity. Biochemistry 1990; 29: 562–569.

    Article  PubMed  CAS  Google Scholar 

  115. Bachur NR, Johnson R, Yu F, Hickey R, Applegreen N, Malkas L. Antihelicase activity of DNA-binding anticancer agents: relationship to guanosine-cytidine intercalator binding. Mol Pharmacol 1993; 44: 1064–1069.

    PubMed  CAS  Google Scholar 

  116. Zunino F, Capranico G. DNA topoisomerase II as the primary target of anti-tumor anthracyclines. Anticancer Drug Design 1990; 5: 307–317.

    CAS  Google Scholar 

  117. Pommier Y. DNA topoisomerases and their inhibition by anthracyclines. In: Priebe W, eds. Antracycline Antibiotics. Washington, DC: American Chemical Society. 1995: 183–203.

    Google Scholar 

  118. Solary E, Ling Y-H, Perez-Soler R, Priebe W, Pommier Y. Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistance. Int J Cancer 1994; 57: 1–10.

    Google Scholar 

  119. Capranico G, Butelli E, Zunino F. Change of the sequence specificity of daunorubicinstimulated topoisomerase II DNA cleavage by epimerization of the amino group of the sugar moiety. Cancer Res 1995; 55: 312–317.

    CAS  Google Scholar 

  120. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984; 226: 466–468.

    Article  PubMed  CAS  Google Scholar 

  121. Zwelling LA, Kerrigan D, Michaels S. Cytotoxicity and DNA strand breaks by 5-iminodaunorubicin in mouse leukemia L1210 cells: comparison with adriamycin and 4 ’-(9-acridinylamino) methanesulfon-m-anisidide. Cancer Res 1982; 42: 2687–2691.

    PubMed  CAS  Google Scholar 

  122. Zwelling LA, Michaels S, Erickson LC, Ungerleider RS, Nichols M, Kohn KW. Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4 ’-(9-acridinylamino) methanesulfon-m-anisidide and adriamycin. Biochemistry 1981; 20: 6553–6563.

    Article  PubMed  CAS  Google Scholar 

  123. Capolongo L, Belvedere G, D’Incalci M. DNA damage and cytotoxicity of mitoxantrone and doxorubicin in doxorubicin-sensitive and -resistant human colon carcinoma cells. Cancer Chemother Pharmacol 1990; 25: 430–434.

    Article  PubMed  CAS  Google Scholar 

  124. Neidle S, Jenkins TC. Molecular modeling to study DNA intercalation by antitumor drugs. Methods Enzymol 1991; 203: 433–458.

    Article  PubMed  CAS  Google Scholar 

  125. Smith PJ, Morgan SA, Fox ME, Watson JV. Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells. Biochem Pharmacol 1990; 40: 2069–2078.

    Article  PubMed  CAS  Google Scholar 

  126. Leteurtre F, Kohlhagen G, Paull KD, Pommier Y. Topoisomerase II inhibition by anthrapyrazoles, DuP 937 and DuP 941 (Losoxanthrone) and cytotoxicity in the NCI cell screen. J Natl Cancer Inst 1994; 86: 1239–1244.

    Article  PubMed  CAS  Google Scholar 

  127. De Isabella P, Capranico G, Palumbo M, Sissi C, Krapcho AP, Zunino F. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationship to drug DNA binding and cellular effects. Mol Pharmacol 1993; 43: 715–721.

    PubMed  Google Scholar 

  128. Capranico G, Palumbo M, Tinelli S, Mabilia M, Pozzan A, Zunino F. Conformational drug determinants of the sequence specificity of drug-stimulated topoisomerase II DNA cleavage. J Mol Biol 1994; 235: 1218–1230.

    Article  PubMed  CAS  Google Scholar 

  129. Harker WG, Slade DL, Drake FH, Parr RL. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic actvity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase IIb iso form. Biochemistry 1991; 30: 9953–9961.

    Article  PubMed  CAS  Google Scholar 

  130. Kamath N, Grabowski D, Ford J, Kerrigan D, Pommier Y, Ganapathi R. Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantrone. Biochem Pharmacol 1992; 44: 937–945.

    Article  PubMed  CAS  Google Scholar 

  131. Yang C-HJ, Horton JK, Cowan KH, Schneider E. Cross-resistance to camptothecin analogues in mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res 1995; 55: 4004–4009.

    PubMed  CAS  Google Scholar 

  132. Harker WG, Slade KL, Parr RL, Feldhoff PW, Sullivan DM, Holguin MH. Alterations in the topoisomerase IIa gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II6 enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Res 1995; 55: 1707–1716.

    PubMed  CAS  Google Scholar 

  133. Cain BF, Atwell GJ. The experimental antitumor properties of three congeners of the acridylmethanesulphonanisilide(AMSA)series. Eur J Cancer 1974; 10: 539–549.

    PubMed  CAS  Google Scholar 

  134. Hayat M, Ostronoff M, Gilles G, Zambon E, Baume D, Moran A. Carde P, Droz J, Pico J. Salvage therapy with methyl-gag,high-dose ara-C,m-amsa, and ifosfamide(MAMI) for recurrent or refractory lymphoma. Cancer Invest 1990; 8: 1–5.

    Article  PubMed  CAS  Google Scholar 

  135. Louie AC, Issel BF. Amsacrine (AMSA)-a clinical review. J Clin Oncol 1985; 3:562–592.

    Google Scholar 

  136. Covey JM, Kohn KW, Kerrigan D, Tilchen EJ, Pommier Y. Topoisomerase II-mediated DNA damage produced by 4 ’-(9-acridinylamino)methanesulfon-m-anisidide and related acridines in L1210 cells and isolated nuclei: relation to cytotoxicity. Cancer Res 1988; 48: 860–865.

    PubMed  CAS  Google Scholar 

  137. Zwelling LA, Mitchell MJ, Satitpunwaycha P, Mayes J, Altschuler E, Hinds M, Baguley BC. Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or -resistant forms of topoisomerase II: use of computer simulation in new drug development. Cancer Res 1992; 52: 209–217.

    PubMed  CAS  Google Scholar 

  138. Harvey VJ, Hardy JR, Smith S, Grove W, Baguley BC. Phase III study of the amsacrine analogue CI-921(NSC343499) in non-small cell lung cancer. Eur J Cancer 1991; 27: 1617–1620.

    Article  PubMed  CAS  Google Scholar 

  139. Sklarin NT, Wiernik PH, Grove WR, Benson L. A phase II trial of CI-921 in advanced malignancies. Invest New Drugs 1992; 10: 309–312.

    Article  PubMed  CAS  Google Scholar 

  140. Pommier Y. Covey JM, Kerrigan D, Markovits J, Pham R. DNA unwinding and inhibition of mouse leukemia L1210 DNA topoisomerase I by intercalators. Nucleic Acids Res 1987; 15: 6713–6731.

    Article  PubMed  CAS  Google Scholar 

  141. Pommier Y, Minford JK, Schwartz RE, Zwelling LA, Kohn KW. Effects of the DNA intercalators 4 ’-(9-acridinylamino)methanesulfon-m-anisidide and 2-methyl-9-hydroxyellipticinium on topoisomerase II mediated DNA strand cleavage and strand passage. Biochemistry 1985; 24: 6410–6416.

    Article  PubMed  CAS  Google Scholar 

  142. Nelson EM, Tewey KM, Liu LF. Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4 ’-(9-acridinylamino)-methanesulfon-m-anisidide. Proc Natl Acad Sci USA 1984; 81: 1361–1365.

    Article  PubMed  CAS  Google Scholar 

  143. Minford J, Pommier Y, Filipski J, Kohn KW, Kerrigan D, Mattem M, Michaels S, Schwartz R, Zwelling LA. Isolation of intercalator-dependent protein-linked DNA strand cleavage activity for cell nuclei and identification as topoisomerase II. Biochemistry 1986; 25: 9–16.

    Article  PubMed  CAS  Google Scholar 

  144. Pommier Y, Covey J, Kerrigan D, Mattes W, Markovits J, Kohn KW. Role of DNA intercalation in the inhibition of purified mouse leukemia (L1210) DNA topoisomerase II by 9-aminoacridines. Biochem Pharmacol 1987; 36: 3477–3486.

    Article  PubMed  CAS  Google Scholar 

  145. Darkin S, Ralph RK. Transport of AMSA drugs into cells. FEBS Lett 1985; 190: 349–353.

    Article  PubMed  CAS  Google Scholar 

  146. Zwelling LA, Kerrigan D, Michaels S, Kohn KW. Cooperative sequestration of m-AMSA in L1210 cells. Biochem Pharmacol 1982; 31: 3269–3277.

    Article  PubMed  CAS  Google Scholar 

  147. Paoletti C, Le Pecq JB, Dat Xuong N, Juret P, Gamier H, Amiel JL, Rouessé J. Antitumor activity, pharmacology, and toxicity of ellipticines, ellipticinium and 9-hydroxy-derivatives: preliminary clinical trials of 2-methyl-9-hydroxy-ellipticinium(NSC-264–137). Recent Res Cancer Res 1980; 74: 107–123.

    Article  CAS  Google Scholar 

  148. Tewey KM, Chen GL, Nelson EM, Liu LF. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Bio! Chem 1984; 259: 9182–9187.

    CAS  Google Scholar 

  149. Pommier Y, Schwartz RE, Zwelling LA, Kohn KW. Effects of DNA intercalating agents on topoisomerase II induced DNA strand cleavage in isolated mammalian cell nuclei. Biochemistry 1985; 24: 6406–6410.

    Article  PubMed  CAS  Google Scholar 

  150. Zwelling LA, Michaels S, Kerrigan D, Pommier Y, Kohn KW. Protein-associated deoxyribonucleic acid strand breaks produced in mouse leukemia L1210 cells by ellipticine and 2-methyl-9-hydroxyellipticinium. Biochem Pharmaco 1982; 31: 3261–3267.

    Article  CAS  Google Scholar 

  151. Pommier Y, Schwartz RE, Kohn KW, Zwelling LA. Formation and rejoining of deoxyribonucleic acid double-strand breaks induced in isolated cell nuclei by antineoplastic intercalating agents. Biochemistry 1984; 23: 3194–3201.

    Article  PubMed  CAS  Google Scholar 

  152. Pommier Y, Kerrigan D, Schwartz RE, Swack JA, McCurdy A. Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors. Cancer Res 1986; 46: 3075–3081.

    PubMed  CAS  Google Scholar 

  153. Pommier Y, Schwartz RE, Zwelling LA, Kerrigan D, Mattem MR, Charcosset JY, JacqueminSablon A, Kohn KW. Reduced formation of protein-associated DNA strand breaks in Chinese hamster cells resistant to topoisomerase II inhibitors. Cancer Res 1986; 46: 611–616.

    PubMed  CAS  Google Scholar 

  154. Andersson BS, Beran M, Bakic M, Silberman LE, Newman RA, Zwelling LA. In vitro toxicity and DNA cleaving capacity of benzisoquinolinedione (nafidimide; NSC 308847) in human leukemia. Cancer Res 1987; 47: 1040–1044.

    PubMed  CAS  Google Scholar 

  155. Hsiang Y-H, Jiang JB, Liu LF. Topoisomerase II-mediated DNA cleavage by amonafide and structural analogs. Mol Pharmacol 1989; 36: 371–376.

    PubMed  CAS  Google Scholar 

  156. Earnshaw WC, Honda BM, Laskey RA, Thomas JO. Assembly of nucleosomes: the reaction involving X. laevis nucleoplasmin. Cell 1980; 21: 373–383.

    Article  PubMed  CAS  Google Scholar 

  157. De Isabella P, Zunino F, Capranico G. Base sequence determinants of amonafide stimulation of topoisomerase II DNA cleavage. Nucleic Acids Res 1995; 23: 223–229.

    Article  PubMed  Google Scholar 

  158. Markovits J, Linassier C, Fosse P, Couprie J, Pierre J, Jacquemin-Sablon A, Saucier J-M, Le Pecq JB, Larsen AK. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res 1989; 49: 5111–5117.

    PubMed  CAS  Google Scholar 

  159. Austin CA, Patel S, Ono K, Nakane H, Fisher LM. Site-specific DNA cleavage by mammalian DNA topoisomerase II induced by novel flavone and catechin derivatives. Biochem J 1992; 282: 883–889.

    PubMed  CAS  Google Scholar 

  160. Yamashita Y, Kawada S-Z, Nakano H. Induction of mammalian topoisomerase II dependent DNA cleavage by nonintercalative flavonoids, genistein and orobol. Biochem Pharmacol 1990; 39: 737–744.

    Article  PubMed  CAS  Google Scholar 

  161. Sorensen BS, Jensen PS, Andersen AH, Christiansen K, Alsner J, Thomsen B, Westergaard O. Stimulation of topoisomerase II mediated DNA cleavage at specific sequence elements by the 2-nitroimidazole Ro 15–0216. Biochemistry 1990; 29: 9507–9515.

    Article  PubMed  CAS  Google Scholar 

  162. Juang J-K, Huang HW, Chen C-M, Liu HJ. A new compound, withangulatin A, promotes type II DNA topoisomerase-mediated DNA damage. Biochem Biophys Res Commun 1989; 159: 1128–1134.

    Article  PubMed  CAS  Google Scholar 

  163. Yamashita Y, Saitoh Y, Ando K, Takahashi K, Ohno H, Nakano H. Saintopin, a new antitumor antibiotic with topoisomerase II dependent DNA cleavage activity, from Paecilomyces. JAntibiotics 1990; 43: 1344–1346.

    Article  CAS  Google Scholar 

  164. Kawada S-Z, Yamashita Y, Fujii N, Nakano H. Induction of heat-stable topoisomerase II-DNA cleavable complex by nonintercalative terpenoides, terpentecin and clerocidin. Cancer Res 1991; 51: 2922–2925.

    PubMed  CAS  Google Scholar 

  165. Kawada S-Z, Yamashita Y, Uosaki Y, Gomi K, Iwasaki T, Takiguchi T, Nakano H. UCT48, a new antitumor antibiotic with topoisomerase II mediated DNA cleavage activity from streptomyces sp. J Antibiot 1992; 45: 1182–1184.

    Article  CAS  Google Scholar 

  166. Leteurtre F, Sackett DL, Madalengoitia J, Kohlhagen G, Macdonald T, Hamel E, Paull KD, Pommier Y. Azatoxin derivatives with potent and selective action on topoisomerase II. Biochem Pharmacol 1995; 49: 1283–1290.

    Article  PubMed  CAS  Google Scholar 

  167. Solary E, Leteurtre F, Paull KD, Scudiero D, Hamel E, Pommier Y. Dual inhibition of topoisomerase II and tubulin polymerization by azatoxin, a novel cytotoxic agent. Biochem Pharmacol 1993; 45: 2449–2456.

    Article  PubMed  CAS  Google Scholar 

  168. Yamasahita Y, Ashizawa T, Marimoto M, Hosomi J, Nakano H. Antitumor quinolones with mammalian topoisomerase II mediated DNA cleavage activity. Cancer Res 1992; 52: 2818–2822.

    Google Scholar 

  169. Elsea SH, Osheroff N, Nitiss JL. Cytotoxicity of Quinolones toward eukaryotic cells. J Biol Chem 1992; 267:13, 150–13, 153.

    Google Scholar 

  170. Froelich-Ammon SJ, McGuirk PR, Gootz TD, Jefson MR, Osheroff N. Novel 1–8-bridged chiral quinolones with activity against topoisomerase II: stereospecificity of the eukaryotic enzyme. Antimicrob Agent Chemother 1993; 37: 646–651.

    Article  CAS  Google Scholar 

  171. Yoshinari T, Mano E, Arakawa H, Kurama M, Iguchi T, Nakagawa S, Tanaka N, Okura A. Stereo(C7)-dependent topoisomerase II inhibition and tumor growth suppression by a new quinolone, BO-2367. Jpn J Cancer Res 1993; 84: 800–806.

    Article  PubMed  CAS  Google Scholar 

  172. Kong XB, Rubin L, Chen LI, Ciszewska G, Watanabe KA, Tong WP, Sirotnak FM, Chou TC. Topoisomerase II-mediated DNA cleavage activity and irreversibility of cleavable complex formation induced by DNA intercalator with alkylating capability. Mol Pharmacol 1992; 41: 237–244.

    PubMed  CAS  Google Scholar 

  173. Ono K, Ikegami Y, Nishizawa M, Andoh T. Menogaril, an anthracycline derivative, inhibits DNA topoisomerase II by stabilizing cleavable complexes. Jpn J Cancer Res 1992; 83: 1018–1023.

    Article  PubMed  CAS  Google Scholar 

  174. Fujii N, Yamashita Y, Arima Y, Nagashima M, Nakano H. Induction of topoisomerase II-mediated DNA cleavage by the plant naphthoquinones plumbagin and shikonin. Antimicrob Agents Chemother 1992; 36: 2589–2594.

    Article  PubMed  CAS  Google Scholar 

  175. Fujii N, Yamashita Y, Chiba S, Uosaki Y, Saitoh Y, Tuji Y, Nakano H. UCE6, a new antitumor antibiotic with topoisomerase I mediated DNA cleavage activity, from actinomycetes (letter). J Antibiot 1993; 46: 1173, 1174.

    Google Scholar 

  176. Gupta M, Abdel-Megeed M, Hoki Y, Kohlhagen G. Paull K, Pommier Y. Eukaryotic DNA topoisomerase mediated DNA cleavage induced by a new inhibitor: NSC 665517. Mol Pharmacol 1995; 48: 658.

    PubMed  CAS  Google Scholar 

  177. Macdonald TL, Lehnert EK, Loper JT, Chow K-C, Ross WE. On the mechanism of interaction of DNA topoisomerase II with chemotherapeutic agents. In: Potmesil M, Kohn KW, eds. DNA Topoisomerase in Cancer. New York: Oxford University Press. 1991: 199–214.

    Google Scholar 

  178. Eymin B, Solary E, Chevillard S, Dubrez L, Goldwasser F, Duchamp O, Genne P, Leteurtre F, Pommier Y. Cellular pharmacology of azatoxins (topoisomerase II and tubulin inhibitors) in P-glycoprotein-positive and negative cell lines. Int J. Cancer 1995; 63: 268–275.

    Article  PubMed  CAS  Google Scholar 

  179. Rowe T, Kupfer G, Ross W. Inhibition of epipodophyllotoxin cytotoxicity by interference with topoisomerase-mediated DNA cleavage. Biochem Pharmacol 1985; 34: 2483–2487.

    Article  PubMed  CAS  Google Scholar 

  180. Markovits J, Pommier Y, Mattem MR, Esnault C, Roques BP, Le Pecq JB, Kohn KW. Effects of the bifunctional antitumor intercalator ditercalinium on DNA in mouse leukemia L1210 cells and DNA topoisomerase H. Cancer Res 1986; 46: 5821–5826.

    PubMed  CAS  Google Scholar 

  181. Fesen M, Pommier Y. Mammalian topoisomerase II activity is modulated by the DNA minor groove binder distamyhcin in simian virus 40 DNA. J Biol Chem 1989; 19:11, 354–11, 359.

    Google Scholar 

  182. Drake FH, Hofmann GA, Mong SM, Bartus JO, Hertzberg RP, Johnson RK, Mattem MR, Mirabelli CK. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res 1989; 49: 2578–2583.

    PubMed  CAS  Google Scholar 

  183. Ishida R, Miki T, Narita T, Yui R, Sato M, Utsumi KR, Tanabe K, Andoh T. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: modes of cell growth inhibition distinct from that of cleavable complex-forming inhibitors. Cancer Res 1991; 51: 4909–4916.

    PubMed  CAS  Google Scholar 

  184. Tanabe K, Ikegami R, Andoh T. Inhibition of topoisomerase II by antitumor agent bis(2,6dioxopiperazine). Cancer Res 1991; 51: 4903–4908.

    PubMed  CAS  Google Scholar 

  185. Bojanowski K, Lelievre S, Markovits J, Couprie J, Jacquemin-Sablon A, Larsen AK. Suramin is an inhibitor of DNA topoisomerase II in vitro and in chinese hamster fibrosarcoma cells. Proc Natl Acad Sci USA 1992; 89: 3025–3029.

    Article  PubMed  CAS  Google Scholar 

  186. Gedik CM, Collins AR. Comparison of effects of fostriecin, novobiocin, and camptothecin, inhibitors of DNA topoisomerases, on DNA replication and repair in human cells. Nucleic Acids Res 1990; 18: 1007–1013.

    Article  PubMed  CAS  Google Scholar 

  187. Frosina G, Rossi O. Effect of topoisomerase poisoning by antitumor drugs VM 26, fostriecin and camptothecin on DNA repair replication by mammalian cell extracts. Carcinogenesis 1992; 13: 1371–1377.

    Article  PubMed  CAS  Google Scholar 

  188. Boritzki TJ, Wolfard TS, Besserer JA, Jackson RC, Fry DW. Inhibition of type II topoisomerase by fostriecin. Biochem Pharmacol 1988; 37: 4063–4068.

    Article  PubMed  CAS  Google Scholar 

  189. Jensen PB, Jensen PS, Demant EJF, Friche E, Sorensen BS, Sehested M, Wassermann K, Vindelov L, Westergaard O, Hensen HH. Antagonistic effect of aclarubicin on daunorubicininduced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II. Cancer Res 1991; 51: 5093–5099.

    PubMed  CAS  Google Scholar 

  190. Herman EH, Witiak K, Hellman K, Waravdekar VS. Biological properties of ICRF-159 and related bis(dioxopiperazine) compounds. In: Garattini A, Goldin F, Hawking F, Kopin IJ, eds. Advances in Pharmacology and Chemotherapy. New York: Academic. 1982: 249–291.

    Google Scholar 

  191. Ishida R, Sato M, Narita T, Utsumi KR, Nishimoto T, Morita T, Nagata H, Andoh T. Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events. J Bio! Chem 1994; 26: 1341–1351.

    Google Scholar 

  192. Takasuga Y, Andoh T, Yamashita J, Yagura T. ICRF-193, an inhibitor of topoisomerase II, demonstrates that DNA replication in sperm nuclei reconstituted in Xenopus egg extracts does not require chromatin decondensation. Exp Cell Res 1995; 217: 378–384.

    Article  PubMed  CAS  Google Scholar 

  193. Narita T, Yaguchi S, Komatsu T, Takase M, Hoshino A, Inaba M, Tsukagoshi S. Antitumor activity of MST-16, a novel derivative of bis(2,6-dioxopiperazine), in murine models. Cancer Chemother Pharmacol 1990; 26: 193–197.

    Article  PubMed  CAS  Google Scholar 

  194. Narita T, Koide Y, Yaguchi S, Kimura S, Izumisawa Y, Takase M, Inaba M, Tsukagoshi S. Antitumor activities and schedule dependence of orally administered MST-16, a novel derivative of bis(2,6-dioxopiperazine). Cancer Chemother Pharmacol 1991; 28: 235–240.

    PubMed  CAS  Google Scholar 

  195. Ohno R, Yamada K, Hirano M, Shirakawa S, Tanaka M, Oguri T, Kodera Y, Mitomo Y, Ikeda Y, Yokomaku S, et al. Phase II study: treatment of non-Hodgkin’s lymphoma with an oral antitumor derivative of bis(2,6-dioxopiperazine). J Natl Cancer Inst 1992; 84: 435–438.

    Article  PubMed  CAS  Google Scholar 

  196. Ichihashi T, Kiyoi H, Fukutani H, Kubo K, Yamauchi T, Naoe T, Yamada K, Ohno R. Effective treatment of adult T cell leukemia/lymphoma with a novel oral antitumor agent, MST-16. Oncology 1992; 49: 333–335.

    Article  PubMed  CAS  Google Scholar 

  197. Ohno R, Masaoka T, Shirakawa S, Sakamoto S, Hirano M, Hanada S, Yasunage K, Yokomaku S, Mitomo Y, Nagai K, et al. Treatment of adult T-cell leukemia/lymphoma with MST-16, a new oral antitumor drug and a derivative of bis(2,6-dioxopiperazine). The MST-16 Study Group. Cancer 1993; 71: 2217–2221.

    Article  PubMed  CAS  Google Scholar 

  198. Seifert CF, Nesser ME, Thompson DF. Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity [published erratum appears in Ann Pharmacother 1994 Dec;28(12):1413]. Ann Pharmacother 1994; 28: 1063–1072.

    Google Scholar 

  199. Buss JL, Hasinoff BB. Ferrous ion strongly promotes the ring opening of the hydrolysis intermediates of the antioxidant cardioprotective agent dexrazoxane (ICRF-187). Arch Biochem Biophys 1995; 317: 121–127.

    Article  PubMed  CAS  Google Scholar 

  200. Buss JL, Hasinoff BB. The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes. Agents Actions 1993; 40: 86–95.

    Article  PubMed  CAS  Google Scholar 

  201. Cooney DA, Covey JM, Kang GJ, Dalai M, McMahon JB, Johns DG. Initial mechanistic studies with merbarone (NSC 336628). Biochem Pharmacol 1985; 34: 3395–3398.

    Article  PubMed  CAS  Google Scholar 

  202. Chen M, Beck WT. Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26. Cancer Res 1995; 55: 1509–1515.

    PubMed  CAS  Google Scholar 

  203. Chen M, Beck WT. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase IIa, when treated with the non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme. Cancer Res 1993; 53: 5946–5953.

    PubMed  CAS  Google Scholar 

  204. Flanigan RC, Saiers JH, Wolf M, Kraut EH, Smith AY, Blumenstein B, Crawford ED. Phase II evaluation of merbarone in renal cell carcinoma. Invest New Drugs 1994; 12: 147–149.

    Article  PubMed  CAS  Google Scholar 

  205. Poplin EA, Tangen CM, Harvey WH, Macdonald JS. Hepatoma/merbarone. A Southwest Oncology Group study. Invest New Drugs 1994; 12: 337–340.

    Article  PubMed  CAS  Google Scholar 

  206. Jones DV, Jr., Ajani JA, Winn RJ, Daugherty KR, Levin B, Krakoff IH. A phase II study of merbarone in patients with adenocarcinoma of the pancreas. Cancer Invest 1993; 11: 667–669.

    Article  PubMed  Google Scholar 

  207. Kraut EH, Bendetti J, Balcerzak SP, Doroshow JH. Phase II trial of merbarone in soft tissue sarcoma. A Southwest Oncology Group study. Invest New Drugs 1992; 10: 347–249.

    Article  PubMed  CAS  Google Scholar 

  208. Ajani JA, Winn R, Baez L, Pollock T, Maher T, Hallinan-Fueger B, Newman J. Phase II study of merbarone (NSC 336628) in patients with advanced gastric carcinoma. Cancer Invest 1994; 12: 488–490.

    Article  PubMed  CAS  Google Scholar 

  209. Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D. Phase II study of taxol, mer-barone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results (see comments). J Natl Cancer Inst 1993; 85: 388–394.

    Article  PubMed  CAS  Google Scholar 

  210. Jackson RC, Fry DW, Boritzki TJ, Roberts BJ, Hook KE, Leopold WR. The biochemical pharmacology of CI-920, a structurally novel antibiotic with antileukemic activity. Adv Enzyme Regul 1985; 23: 193–215.

    Article  PubMed  CAS  Google Scholar 

  211. Scheithauer W, Von Hoff DD, Clark GM, Shillis JL, Elslager EF. In vitro activity of the novel antitumor antibiotic fostriecin (CI-920) in a human tumor cloning assay. Eur J Cancer Clin Oncol 1986; 22: 921–926.

    Article  PubMed  CAS  Google Scholar 

  212. Baguley BC, Calveley SB, Crowe KK, Fray LM, O’Rourke SA, Smith GP. Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor alpha on colon 38 tumours in mice. Eur J Cancer Clin Oncol 1989; 25: 263–269.

    Article  CAS  Google Scholar 

  213. Roberge M, Tudan C, Hung SM, Harder KW, Jirik FR, Anderson H. Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A. Cancer Res 1994; 54: 6115–6121.

    PubMed  CAS  Google Scholar 

  214. Guo XW, Th’ng JP, Swank RA, Anderson HJ, Tudan C, Bradbury EM, Roberge M. Chromosome condensation induced by fostriecin does not require p34cdc2 kinase activity and histone H1 hyperphosphorylation, but is associated with enhanced histone H2A and H3 phosphorylation. EMBO J 1995; 14: 976–985.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Yves Pommier MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Dana-Farber Cancer Institute, Boston, MA, USA

    Beverly A. Teicher

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer Science+Business Media New York

About this chapter

Cite this chapter

Pommier, Y. (1997). DNA Topoisomerase II Inhibitors. In: Teicher, B.A. (eds) Cancer Therapeutics. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-717-8_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-717-8_7

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-046-5

  • Online ISBN: 978-1-59259-717-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation